Browsing Tag
small-cap biotech
4 posts
VolitionRx Limited faces NYSE compliance deadline tied to sustained sub-US$1 share price
VolitionRx Limited receives a NYSE non-compliance notice tied to its share price. Find out what it means for investors, strategy, and what comes next.
Can C4 Therapeutics (CCCC) balance dilution and growth with its $400m shelf plan?
C4 Therapeutics files $400M shelf to support oncology trials. Find out what this means for investors and the company’s future strategy.
Is Ernexa Therapeutics (NASDAQ: ERNA) turning into the next small‑cap biotech breakout?
Is Ernexa Therapeutics (NASDAQ: ERNA) the next small-cap biotech breakout? Learn how its iMSC platform and Cellipont partnership could change its trajectory.
Vectus Biosystems (ASX:VBS) exits VB4-P5—can this microcap regain momentum with VB0004?
Vectus Biosystems signs US$3M deal to license VB4-P5 to XORTX. Can its lead fibrosis drug VB0004 now deliver the next big upside?